Literature DB >> 9809646

Characterization of immunoreactive dynorphin B and beta-endorphin in human plasma.

J Silberring1, Y M Li, L Terenius, I Nylander.   

Abstract

Dynorphins and beta-endorphin in human plasma were characterized and studied quantitatively using radioimmunoassay, high-performance liquid chromatography (HPLC), and mass spectrometry. Most immunoreactive (ir) dynorphin B and beta-endorphin in human plasma coeluted with authentic peptides in analysis. Dynorphin A was not detected. Added to human plasma it was rapidly converted into Leu-enkephalin-Arg6 followed by elimination of the C-terminal arginine after prolonged incubation. The rate of dynorphin A conversion was estimated at 40 pmol/min/microl plasma. This process was inhibited by the thiol protease inhibitor, PHMB and by EDTA. Dynorphin B, alpha-neoendorphin and big dynorphin were virtually not metabolized by plasma proteases under the same conditions. beta-endorphin was processed into beta-endorphin(1-19) and the corresponding C-terminal counterpart beta-endorphin(20-31) at a rate of about 25 pmol/min/microl of plasma. Based on the above data, a reliable strategy was established to measure dynorphin B- and beta-endorphin-ir in human plasma samples. The basal levels in a male control group were 0.99 +/- 0.11 (n = 11) and 16.3 +/- 1.5 (n = 11) fmol/ml plasma, respectively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809646     DOI: 10.1016/s0196-9781(98)00079-5

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Effect of beta-endorphin and DAGO, a selective agonist of mu-opioid receptors, on the proliferative activity of lymphocytes.

Authors:  S V Gein; T A Simonenko; V A Chereshnev
Journal:  Dokl Biol Sci       Date:  2003 Jul-Aug

2.  Dynorphin peptides differentially regulate the human kappa opioid receptor.

Authors:  Yong Chen; Chongguang Chen; Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2007-01-20       Impact factor: 5.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.